Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study.

Published in: Investigative and clinical urology (2020)

Docetaxel rechallenge showed meaningful anti-tumor activity with acceptable toxicity in heavily pretreated patients with mCRPC.

Keyphrases